| ALK |
EML4-ALK |
ALK inhibitor |
Crizotinib |
Advanced Cancer |
Completed |
Phase 1 |
NCT01576406 |
| ALK |
EML4-ALK |
ALK inhibitor |
Crizotinib |
patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive |
FDA-Approved |
|
|
| ALK |
EML4-ALK |
ALK inhibitor |
ceritinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 1 |
NCT02299505 |
| ALK |
EML4-ALK |
ALK inhibitor |
ceritinib |
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer |
FDA-Approved |
|
|
| ALK |
EML4-ALK |
ALK inhibitor |
alectinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 1Phase 2 |
NCT01871805 |
| ALK |
EML4-ALK |
ALK inhibitor |
alectinib |
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) |
FDA-Approved |
|
|
| ALK |
EML4-ALK |
ALK inhibitor |
AP26113 |
Carcinoma,Non-Small-Cell Lung |
Completed |
Phase 2 |
NCT02094573 |
| ALK |
EML4-ALK |
ALK inhibitor |
ASP3026 |
Solid Tumor |
Completed |
Phase 1 |
NCT01401504 |
| ALK |
EML4-ALK |
ALK inhibitor |
brigatinib |
Carcinoma,Non-Small-Cell Lung |
Completed |
Phase 2 |
NCT02094573 |
| ALK |
EML4-ALK |
ALK inhibitor |
brigatinib |
patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) |
FDA-Approved |
|
|
| ALK |
EML4-ALK |
ALK inhibitor |
lorlatinib |
ALK Positive Non-small Cell Lung Cancer |
Recruiting |
Phase 2 |
NCT06092086 |
| ALK |
EML4-ALK |
ALK inhibitor |
lorlatinib |
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) |
FDA-Approved |
|
|
| ALK |
EML4-ALK |
ALK、ROS1 and MET alterations |
克唑替尼(Crizotinib，赛可瑞，Xalkori) |
Unresectable,recurrent,or refractory ALK-positive IMT/ALCL,Unresectable or metastatic ALK-positive NSCLC |
FDA/NMPA approved |
|
|
| ALK |
EML4-ALK |
ALK ( C1156Y,G126 9A,S1206Y and L1152R mutations but not G1202R) and RET alterations |
艾乐替尼(阿来替尼，Alecensa，Alectinib) |
Unresectable or metastatic ALK-positive NSCLC |
FDA/NMPA approved |
|
|
| ALK |
EML4-ALK |
ALK (L1196M G1 269 EA IM 1171T,and S1206Y etc.),IGF1R,and ROS1 alterations |
色瑞替尼(Ceritinib,Zykadia) |
Unresectable or metastatic ALK-positive NSCLC |
FDA/NMPA approved |
|
|
| ALK |
EML4-ALK |
ALK and ROS1 fusions,ALK mutations,EGFR L858R, |
布加替尼(Brigatinib，Alunbrig) |
Unresectable or metastatic ALK-positive NSCLC |
FDA approved |
|
|
| ALK |
EML4-ALK |
ALK,ROS1,TRK1/2/3 |
恩沙替尼 (Ensartinib) |
patients who have progressed after previous Crizotinib treatment and are unable to tolerate Crizotinib,Patients who are positive for ALK mutations with locally advanced or metastatic NSCLC |
FDA/NMPA approved |
|
|
| ALK |
EML4-ALK |
ALK，ROS1 |
劳拉替尼 (Lorlatinib，Lorbrena) |
Unresectable or metastatic ALK-positive NSCLC |
FDA approved |
|
|
| ALK |
EML4-ALK |
ALK inhibitor |
TQ-B3139 |
ALK-positive NSCLC |
unknown status |
Phase 3 |
NCT04009317 |
| ALK |
EML4-ALK |
ALK inhibitor |
WX-0593 |
ALK Positive Non-Small Cell Lung Cancer |
unknown status |
Phase 3 |
NCT04632758 |
| ALK |
EML4-ALK |
ALK inhibitor |
Alkotinib |
ALK-positive Non-small Cell Lung Cancer |
Recruiting |
Phase 2 |
NCT04211922 |
| ALK |
EML4-ALK |
ALK inhibitor |
Entrectinib (RXDX-101) |
solid tumors that harbor an NTRK1/2/3,ROS1,or ALK gene fusion |
Active,not recruiting |
Phase 2 |
NCT02568267 |
| ALK |
EML4-ALK |
ALK inhibitor |
Oral repotrectinib (TPX-0005) |
Advanced Solid Tumors Harboring ALK,ROS1,or NTRK1-3 Rearrangements (TRIDENT-1) |
Recruiting |
phase 1/2 |
NCT03093116 |
| ALK |
EML4-ALK |
ALK inhibitor |
SAF-189s |
ALK/ROS1 positive advanced non-small cell lung cancer |
Recruiting |
phase 1/2 |
NCT04849273 |
| ALK |
EML4-ALK |
ALK inhibitor |
PLB1003 |
ALK+ NSCLC |
unknown status |
phase 1 |
NCT03130881 |
| ALK |
EML4-ALK |
ALK inhibitor |
Alkotinib |
ALK+ NSCLC |
Recruiting |
phase 1 |
NCT03607188 |
| ALK |
EML4-ALK |
ALK inhibitor |
XZP-3621 |
ALK or ROS1 Rearrangement Non-small Cell Lung Cancer |
unknown status |
phase 1 |
NCT05055232 |
| ALK |
EML4-ALK |
ALK inhibitor |
CT-707 |
ALK+ NSCLC |
unknown status |
phase 1 |
NCT02695550 |
| ATM |
ATM |
ATM inhibitor |
Olaparib |
Ovarian Cancer |
Completed |
Early Phase 1 |
NCT04041128 |
| ATM |
ATM |
ATM inhibitor |
Olaparib |
Breast Cancer |
Completed |
Early Phase 1 |
NCT04041128 |
| ATM |
ATM |
ATM inhibitor |
Olaparib |
treat a number of BRCA-associated tumours,including ovarian cancer,breast cancer,pancreatic cancer,and prostate cancer |
FDA-Approved |
|
|
| ATM |
ATM |
ATM |
M4076+M1774 |
Metastatic or Locally Advanced Unresectable Solid Tumors |
Recruiting |
Phase 1 |
NCT05396833 |
| ATM |
ATM |
ATM |
AZD1390+Radiation |
Soft Tissue Sarcoma Adult |
Recruiting |
Phase 1 |
NCT05116254 |
| ATM |
ATM |
ATM |
AZD0156+Olaparib,irinotecan,fluorouracil,folinic acid |
Advanced Solid Tumours |
Completed |
Phase 1 |
NCT02588105 |
| ATM |
ATM |
ATM and DNA-PKcs |
XRD-0394+Palliative radiotherapy |
Metastatic cancer,locally advanced solid tumors,recurrent cancer |
Completed |
Phase 1 |
NCT05002140 |
| ATM |
ATM |
ATM and DNA-PKcs |
KU-60019 |
Kidney Cancer |
Recruiting |
Not Applicable |
NCT03571438 |
| ATR |
ATR |
ATR |
VX-970+Veliparib,cisplatin,topotecan,berzosertib,gemcitabine,radiation therapy,carboplatin,pembrolizumab,irinotecan,topotecan,avelumab |
Neoplasms |
Completed |
Phase 1 |
NCT02723864 |
| ATR |
ATR |
ATR |
M1774+Niraparib |
Advanced unresectable solid tumors |
Recruiting |
Phase 1 |
NCT04170153 |
| ATR |
ATR |
ATR |
AZD6738+Durvalumab,paclitaxel,olaparib,gemcitabine,radiotherapy,trastuzumab,deruxtecan,acalabrutinib,carboplatin,fulvestrant,neratinib,vistusertib |
Bile Duct Cancer |
Recruiting |
Phase 2 |
NCT04298008 |
| ATR |
ATR |
ATR |
RP-3500+Gemcitabine,talazoparib |
Advanced solid tumor |
Active,not recruiting |
Phase 1Phase 2 |
NCT04497116 |
| ATR |
ATR |
ATR |
ART0380+Gemcitabine,irinotecan |
Advanced or metastatic solid tumors |
Recruiting |
Phase 1Phase 2 |
NCT04657068 |
| ATR |
ATR |
ATR |
VX-803+Carboplatin,niraparib |
Advanced solid tumors,recurrent ovarian cancer |
Completed |
Phase 1 |
NCT02278250 |
| ATR |
ATR |
ATR |
ATRN-119+– |
Advanced solid tumors |
Recruiting |
Phase 1Phase 2 |
NCT04905914 |
| ATR |
ATR |
ATR |
Drug: M6620+Drug: Gemcitabine+Drug: Cisplatin |
Advanced Solid Tumor |
Completed |
Phase 1 |
NCT02157792 |
| ATR |
ATR |
ATR |
Drug: Berzosertib
Drug: Carboplatin
Drug: Gemcitabine Hydrochloride
2 more |
Metastatic Fallopian Tube Carcinoma |
Active,not recruiting |
Phase 1 |
NCT02627443 |
| ATR |
ATR |
ATR |
Drug: Administration of ceralasertib
Drug: Administration of ceralasertib in combination with olaparib
Drug: Administation of ceralasertib in combination with durvalumab |
Adv Solid Malig - H&N SCC,ATM Pro / Def NSCLC,Gastric,Breast and Ovarian Cancer |
Recruiting |
Phase 1Phase 2 |
NCT02264678 |
| ATR |
ATR |
ATR |
Drug: AZD6738 |
Solid Tumour Refractory to Conventional Treatment |
Active,not recruiting |
Phase 1 |
NCT02223923 |
| ATR |
ATR |
ATR |
Drug: Administration of AZD6738 |
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), |
Completed |
Phase 1 |
NCT01955668 |
| BRAF |
BRAF,CRAF |
BRAF(V600E),BRAF,CRAF,ABL-1,C-KIT,RET,PDGFRB,VEGFR2,CSF-1R,CSF-1R,EGFR |
Agerafenib (RXDX-105,CEP-32496) |
Solid Tumors |
Completed |
Phase 1 |
NCT03784378,NCT01877811 |
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF,NRAS Mut |
ARQ736 |
Solid Tumors |
Completed |
Phase 1 |
NCT01225536 |
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF |
Belvarafenib (HM95573) |
Neoplasms |
Completed |
Phase 1 |
NCT02405065 |
| BRAF |
ARAF,BRAF,CRAF |
ARAF,BRAF,CRAF,BRAF(V600E) |
CCT3833 (BAL3833) |
Advanced Solid Tumours |
Completed |
Phase 1 |
NCT02437227 |
| BRAF |
BRAF |
BRAF(V600E) |
Dabrafenib (GSK2118436) |
BRAF(V600E/K) melanoma |
approved |
|
|
| BRAF |
CRAF. BRAF |
CRAF. BRAF,VEGFR2,VEGFR3 |
Donafenib (Sorafenib D3) |
Renal cell carcinoma,hepatocellular carcinomas,thyroid cancer |
approved |
|
|
| BRAF |
BRAF |
BRAF(V600E) |
Encorafenib (LGX818) |
BRAF(V600E) colorectal cancer |
approved |
|
|
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF,EGFR,EGFR (T790 M/L858R) |
Lifirafenib (BGB-283) |
Solid Tumors |
Completed |
Phase 1 |
NCT03641586,NCT02610361 |
| BRAF |
BRAF,CRAF |
BRAF,CRAF |
LXH254 |
Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma |
ACTIVE,NOT RECRUITING |
Phase 1/2 |
NCT04417621,NCT02974725 |
| BRAF |
BRAF |
BRAF,BRAF(V600E) |
MLN2480 (TAK-580) |
Relapsed or Refractory Solid Tumors |
Completed |
Phase 1 |
NCT01425008,NCT02327169 |
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF |
FORE8394 |
Advanced Unresectable Solid Tumors,BRAF-mutated Tumors |
ACTIVE,NOT RECRUITING |
Phase 1/2 |
NCT02428712 |
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF,VEGFR2 |
RAF265 (CHIR-265) |
Metastatic Melanoma |
Completed |
Phase 1/2 |
NCT00304525 |
| BRAF |
BRAF,CRAF |
CRAF1,BRAF and BRAF(V600E),VEGFR1,VEGFR2,VEGFR3,PDGFRβ |
Regorafenib (BAY 73-4506) |
Metastatic colorectal cancer,Gastrointestinal stromal tumours |
approved |
|
|
| BRAF |
BRAF,CRAF |
BRAF(V600E),BRAF,CRAF,MEK1 |
RO5126766 (VS-6766,CH5126766) |
Advanced Solid Tumors |
Completed |
Phase 1 |
NCT00773526 |
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF,VEGFR3,VEGFR2,PDGFRβ,C-KIT,Flt3 |
Sorafenib |
Liver and kidney cancer |
approved |
|
|
| BRAF |
BRAF |
BRAF(V600E) |
Vemurafenib (PLX4032) |
BRAF(V600E) melanoma |
approved |
|
|
| BRAF |
BRAF,CRAF |
BRAF,BRAF(V600E),CRAF |
XL281 |
Solid Tumors |
Completed |
Phase 1 |
NCT00451880 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Niraparib (MK-4827) |
Solid Tumors |
Completed |
Phase 1 |
NCT00749502 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Niraparib (MK-4827) |
epithelial ovarian,fallopian tube,or primary peritoneal cancer |
FDA-Approved |
|
|
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Olaparib (AZD-2281) |
Ovarian Carcinoma |
Completed |
Phase 2 |
NCT00679783 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Talazoparib (BMN-673) |
Metastatic Cancer |
Completed |
Phase 1 |
NCT02049593 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Talazoparib (BMN-673) |
adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer |
FDA-Approved |
|
|
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Rucaparib (AG-014699) |
Advanced Solid Tumors |
Completed |
Phase 1 |
NCT01009190 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Rucaparib (AG-014699) |
patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies |
FDA-Approved |
|
|
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Pamiparib (BGB-290) |
Locally Advanced or Metastatic Solid Tumors |
Completed |
Phase 1Phase 2 |
NCT03150810 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Pamiparib (BGB-290) |
patients with germline BRCA mutation-associated recurrent advanced ovarian,fallopian tube,or primary peritoneal cancer who have been treated with two or more lines of chemotherapy |
FDA-Approved |
|
|
| BRCA1 |
BRCA1 |
PARP Inhibitors |
Veliparib (ABT-888) |
Prostate Cancer |
Completed |
Phase 1 |
NCT01085422 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
AZD7648 |
Advanced Malignancies |
Completed |
Phase 1Phase 2 |
NCT03907969 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
CC-115 |
Prostate Cancer |
Completed |
Phase 1 |
NCT02833883 |
| BRCA1 |
BRCA1 |
PARP Inhibitors |
M9831 (VX-984) |
Advanced Solid Tumor |
Completed |
Phase 1 |
NCT02644278 |
| CDKN1B |
P27 |
P27 activator |
bortezomib |
Leukemia |
Completed |
Early Phase 1 |
NCT00437086 |
| CDKN1B |
P27 |
P27 activator |
bortezomib |
adult patients with mantle cell lymphoma |
FDA-Approved |
|
|
| CDKN1B |
P27 |
p27🡹 |
EGCG |
Colon Cancer |
Recruiting |
Early Phase 1 |
NCT02891538 |
| CDKN1B |
P27 |
p27🡹 |
Green tea extract |
Asthma |
Completed |
Not Applicable |
NCT01187147 |
| CDKN1B |
P27 |
p27🡹 |
Green tea extract |
genital warts |
FDA-Approved |
|
|
| CDKN1B |
P27 |
nuclear p27🡻 |
Resveratrol |
Chronic Subclinic Inflammation |
Completed |
Phase 3 |
NCT01492114 |
| CDKN1B |
P27 |
nuclear p27🡻 |
Resveratrol |
Friedreich Ataxia |
Active,not recruiting |
Phase 2 |
NCT03933163 |
| CDKN1B |
P27 |
p27🡹 |
Acteoside |
IGA Nephropathy |
Unknown status |
Phase 2Phase 3 |
NCT02662283 |
| CDKN1B |
P27 |
p27🡻 |
Hydroxytyrosol + |
Mitochondrial Diseases |
Recruiting |
Not Applicable |
NCT04543968 |
| EGFR |
EGFR |
exon19 deletion |
Gefitinib |
Skin Cancer |
Completed |
Phase 2 |
NCT00054691 |
| EGFR |
EGFR |
exon19 deletion |
Gefitinib |
Head and Neck Cancer |
Completed |
Phase 1 |
NCT00681967 |
| EGFR |
EGFR |
exon19 deletion |
Gefitinib |
first-line treatment of patients with metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitution mutations |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
erlotinib |
Kidney Cancer |
Completed |
Phase 2 |
NCT00045487 |
| EGFR |
EGFR |
exon19 deletion |
erlotinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 2 |
NCT00200395 |
| EGFR |
EGFR |
exon19 deletion |
erlotinib |
TARCEVA is a kinase inhibitor indicated for:
• Maintenance treatment of patients with locally advanced or metastatic
non-small cell lung cancer (NSCLC) whose disease has not progressed
after four cycles of platinum-based first-line chemotherapy. (1.1)
• Treatment of locally advanced or metastatic non-small cell lung cancer
after failure of at least one prior chemotherapy regimen. (1.1)
• First-line treatment of patients with locally advanced,unresectable or
metastatic pancreatic cancer,in combination with gemcitabine. (1.2) |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
Afatinib |
Advanced Lymphoma |
Active,not recruiting |
Phase 2 |
NCT04439136 |
| EGFR |
EGFR |
exon19 deletion |
Afatinib |
Advanced Malignant Solid Neoplasm |
Active,not recruiting |
Phase 2 |
NCT04439136 |
| EGFR |
EGFR |
exon19 deletion |
Afatinib |
treatment of patients with metastatic non-small cell lung cancer (NSCLC) |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
Afatinib |
Hematopoietic and Lymphoid Cell Neoplasm |
Active,not recruiting |
Phase 2 |
NCT04439136 |
| EGFR |
EGFR |
exon19 deletion |
dacomitinib |
Non-small Cell Lung Cancer |
Completed |
Phase 2 |
NCT01858389 |
| EGFR |
EGFR |
exon19 deletion |
dacomitinib |
Penile Neoplasms |
Completed |
Phase 2 |
NCT01728233 |
| EGFR |
EGFR |
exon19 deletion |
dacomitinib |
for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
Osimertinib |
Lung Cancer |
Not yet recruiting |
Phase 2 |
NCT04988607 |
| EGFR |
EGFR |
exon19 deletion |
Osimertinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 2 |
NCT02841579 |
| EGFR |
EGFR |
exon19 deletion |
Osimertinib |
treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC),as detected by an FDA-approved test,who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
Lazertinib |
Non Small Cell Lung Cancer |
Not yet recruiting |
Phase 2 |
NCT06020989 |
| EGFR |
EGFR |
exon19 deletion |
Lazertinib |
Non-small Cell Lung Cancer Stage III |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon19 deletion |
Lazertinib |
EGFR Positive Non-small Cell Lung Cancer |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon19 deletion |
Lazertinib |
Non-squamous Non-small-cell Lung Cancer |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon19 deletion |
Lazertinib |
acquired EGFR T790M mutation population |
FDA approved |
|
|
| EGFR |
EGFR |
exon19 deletion |
ZN-e4 |
Carcinoma,Non-Small-Cell Lung |
Completed |
Phase 1Phase 2 |
NCT03446417 |
| EGFR |
EGFR |
exon20 insertion |
Mobocertinib |
Renal Impairment |
Completed |
Phase 1 |
NCT04056455 |
| EGFR |
EGFR |
exon20 insertion |
Mobocertinib |
Non-Small Cell Lung Cancer |
Active,not recruiting |
Phase 1 |
NCT03807778 |
| EGFR |
EGFR |
exon20 insertion |
Mobocertinib |
for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations |
FDA approved |
|
|
| EGFR |
EGFR |
exon20 insertion |
Amivantamab |
Salivary Gland Cancer |
Recruiting |
Phase 2 |
NCT05074940 |
| EGFR |
EGFR |
exon20 insertion |
Amivantamab |
Esophagogastric Cancer |
Recruiting |
Phase 2 |
NCT05117931 |
| EGFR |
EGFR |
exon20 insertion |
Amivantamab |
adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) |
FDA approved |
|
|
| EGFR |
EGFR |
exon20 T790M |
Osimertinib |
Lung Cancer |
Not yet recruiting |
Phase 2 |
NCT04988607 |
| EGFR |
EGFR |
exon20 T790M |
Osimertinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 2 |
NCT02841579 |
| EGFR |
EGFR |
exon20 T790M |
Osimertinib |
adjuvant therapy in patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations |
FDA approved |
|
|
| EGFR |
EGFR |
exon20 T790M |
Lazertinib |
Non Small Cell Lung Cancer |
Not yet recruiting |
Phase 2 |
NCT06020989 |
| EGFR |
EGFR |
exon20 T790M |
Lazertinib |
Non-small Cell Lung Cancer Stage III |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon20 T790M |
Lazertinib |
EGFR Positive Non-small Cell Lung Cancer |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon20 T790M |
Lazertinib |
Non-squamous Non-small-cell Lung Cancer |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon20 T790M |
Lazertinib |
Non-squamous Non-small-cell Lung Cancer |
Recruiting |
Phase 2 |
NCT05338619 |
| EGFR |
EGFR |
exon20 T790M |
ZN-e4 |
Carcinoma,Non-Small-Cell Lung |
Completed |
Phase 1Phase 2 |
NCT03446417 |
| FGFR4 |
FGFR |
FGF1,FGF2,FGF4 |
FP-1039
(Ligand
Traps) |
Solid Malignancies and Deregulated FGF Pathway Signaling |
COMPLETED |
Phase 1 |
NCT01868022 |
| FGFR4 |
FGFR |
FGFR 1,2,3 and 4 |
ASP5878 |
Solid Tumors |
COMPLETED |
Phase 1 |
NCT02038673 |
| FGFR4 |
FGFR |
VEGFR,FGFR
inhibitor |
Brivanib(BMS-540215) |
Advanced cancers |
COMPLETED |
Phase 1 |
NCT00798252 |
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR,FLT3,C-KIT |
Dovitinib(TKI258) |
Tumor Pathway Activations Inhibited by Dovitinib |
COMPLETED |
Phase 2 |
NCT01831726 |
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR,FLT3,C-KIT |
Dovitinib(TKI258) |
Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer |
COMPLETED |
Phase 2 |
NCT01676714 |
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR |
Lenvatinib (E7080) |
Solid Tumor or Lymphoma |
COMPLETED |
Phase 1 |
NCT00121719 |
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR |
Lenvatinib (E7080) |
Advanced Lung Cancer or Lung Cancer That Has Spread,Who Have Been Previously Treated,Unsuccessfully,With at Least 2 Different Treatments |
COMPLETED |
Phase 2 |
NCT01529112 |
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR |
lenvatinib plus pembrolizumab |
advanced renal cell carcinoma |
FDA approved |
|
|
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR |
lenvatinib (Lenvima,Eisai) plus pembrolizumab (Keytruda,Merck) |
first-line treatment of adult patients with advanced renal cell carcinoma (RCC) |
FDA approved |
|
|
| FGFR4 |
FGFR |
FGFR,PDGFR,VEGFR |
Lenvatinib (E7080) |
For the treatment of patients with locally recurrent or metastatic,progressive,radioactive iodine-refractory differentiated thyroid cancer
(DTC). (1.1)
• In combination with everolimus,for the treatment of patients with
advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. (1.2)
• For the first-line treatment of patients with unresectable hepatocellular
carcinoma (HCC). (1.3)
• In combination with pembrolizumab,for the treatment of patients with
advanced endometrial carcinoma (EC) that is not MSI-H or dMMR who
have disease progression following prior systemic therapy in any setting
and are not candidates for curative surgery or radiation. (1.4 |
FDA approved |
|
|
| FGFR4 |
FGFR |
VEGFR1-3,FGFR1-4,PDGFRα/β,c-Kit and Ret |
Anlotinib (AL3818) |
advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy |
NMPA approved |
|
|
| FGFR4 |
FGFR |
VEGFR1-3,FGFR1-4,PDGFRα/β,c-Kit and Ret |
Anlotinib (AL3818) |
Advanced Soft Tissue Sarcoma |
COMPLETED |
Phase 2 |
NCT01878448 |
| FGFR4 |
FGFR |
ATP-competitive inhibitor of FGFR1-3,FGFR4 and VEGFR2 |
Derazantinib (ARQ 087) |
Advanced Solid Tumors With FGFR Genetic Alterations |
COMPLETED |
Phase 1/2 |
NCT01752920 |
| FGFR4 |
FGFR |
SRC,ABL,FGFR,PDGFR
and VEGFR |
ponatinib(AP24534) |
Metastatic Colorectal Cancer |
COMPLETED |
Phase 3 |
NCT02149108 |
| FGFR4 |
FGFR |
SRC,ABL,FGFR,PDGFR
and VEGFR |
ponatinib(AP24534) |
First Line Treatment of Ovarian Cancer |
COMPLETED |
Phase 3 |
NCT01015118 |
| FGFR4 |
FGFR |
SRC,ABL,FGFR,PDGFR
and VEGFR |
ponatinib(AP24534) |
adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL),two rare blood and bone marrow diseases |
FDA approved |
|
|
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Carcinoma |
Completed |
Phase 1/Phase 2 |
NCT00088556 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Non-Small-Cell Lung |
Completed |
Phase 1/Phase 2/Phase 3 |
NCT00047801 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Breast Neoplasms |
Completed |
Phase 2 |
NCT00035841 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Ovarian Neoplasms |
Completed |
Phase 1/Phase 2 |
NCT00051948 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
B Cell Lymphoma |
Completed |
Phase 2 |
NCT01148108 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Mantle Cell Lymphoma |
Completed |
Phase 2 |
NCT01148108 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Multiple Myeloma |
Completed |
Phase 2 |
NCT01148108 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Fallopian Tube Cancer |
Completed |
Phase 2 |
NCT00022347 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Ovarian Cancer |
Completed |
Phase 2 |
NCT00022347 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
TLK286 |
Primary Peritoneal Cavity Cancer |
Completed |
Phase 2 |
NCT00022347 |
| GSTP1 |
GSTπ |
GSTP inhibitor,small molecule myeloproliferative. |
ezatiostat hydrochloride (Telintra®,TLK199,a half-life: 0.20 hours) |
Myelodysplastic Syndrome (MDS),The syndromes are characterized by ineffective hematopoiesis leading to cytopenia and in a third of patients,by progression to acute myeloid leukemia (AML) |
FDA-Approved |
|
|
| GSTP1 |
GSTπ |
GSTπ inhibitor |
auranofin |
Pain |
Completed |
Phase 2 |
NCT02063698 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
auranofin |
Extensive Stage Small Cell Lung Carcinoma |
Completed |
Phase 1/Phase 2 |
NCT01737502 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
auranofin |
Recurrent Ovarian Epithelial Cancer |
Completed |
Early Phase 1 |
NCT01747798 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
auranofin |
Recurrent Primary Peritoneal Cavity Cancer |
Completed |
Early Phase 1 |
NCT01747798 |
| GSTP1 |
GSTπ |
GSTπ inhibitor,Inhibition of TrxR activity; UPR and ER stress; Activation of NRF2 target genes |
auranofin |
Chronic Lymphocytic Leukemia (CLL) |
Completed |
Phase 2 |
NCT03456700 |
| GSTP1 |
GSTπ |
GSTπ inhibitor,Inhibition of the PKCι-Par6-Ect2-MEK-ERK-MMP10 signaling axis; Targeting of TrxR1; Oxidizes proteins of glycolysis |
auranofin |
Ovarian cancer |
Active,not recruiting |
Phase 2 |
NCT03456700 |
| GSTP1 |
GSTπ |
GSTπ inhibitor,Inhibition of hexokinase; Inhibition of glycolysis; Inhibition of TrxR1; Blockade of PI3K/AKT/mTOR pathway; Induction of apoptosis |
auranofin |
Lung cancer |
Completed |
Phase 1/Phase 2 |
NCT03456700 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
auranofin |
Rheumatoid Arthritis,a systemic,chronic,and inflammatory disease with probable autoimmune etiology and predominant involvement of joints,characterized by symmetrical peripheral polyarthritis,resulting in joint deformity. |
FDA-Approved |
|
|
| GSTP1 |
GSTπ |
GSTπ inhibitor |
Brostallicin |
Multiple Myeloma and Plasma Cell Neoplasm |
Completed |
Phase 1/Phase 2 |
NCT00060203 |
| GSTP1 |
GSTπ |
GSTπ inhibitor |
Brostallicin |
Myxoid Liposarcoma |
Unknown status |
Phase 2 |
NCT00633165 |
| GSTP1 |
GSTπ |
GSTπ inhibitor,N3 position of adenines exposed in (TA) rich sequences in the DNA minor groove |
Brostallicin |
Alzheimer Disease |
Completed |
Phase 2 |
NCT04079803 |
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( |
aprroved |
|
|
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Atopic dermatitis |
approved |
|
|
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
COVID-19 |
approved |
|
|
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Polyarticular juvenile idiopathic arthritis |
COMPLETED |
phase3 |
NCT03773978 |
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Systemic juvenile idiopathic arthritis |
RECRUITING |
phase3 |
NCT04088396 |
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Alopecia areata |
ACTIVE,NOT RECRUITING |
Phase 3 |
NCT03899259 |
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Psoriasis |
COMPLETED |
Phase 2 |
NCT01490632 |
| JAK2 |
JAK |
JAK1,JAK2 |
baricitinib |
Polymyalgia rheumatica |
COMPLETED |
phase2 |
NCT04027101 |
| JAK2 |
JAK |
Janus kinase (JAK)1,JAK2,JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor |
peficitinib |
rheumatoid arthritis. |
aprroved |
|
|
| JAK2 |
JAK |
JAK1 and JAK2 |
Ruxolitinib |
Alopecia areata |
COMPLETED |
Phase 2 |
NCT01950780 |
| JAK2 |
JAK |
JAK1 and JAK2 |
Ruxolitinib |
Psoriasis |
COMPLETED |
Phase 2 |
NCT00617994 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
topical ruxolitinib |
Atopic dermatitis |
COMPLETED |
phase3 |
NCT03745638 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
topical ruxolitinib |
Hidradenitis suppurativa |
RECRUITING |
Phase 2 |
NCT04414514 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
topical ruxolitinib |
Alopecia areata |
COMPLETED |
Phase 3 |
NCT03745638 |
| JAK2 |
JAK |
JAK1,JAK2,TYK2,and JAK3 |
topical delgocitinib |
adult moderate-to-severe chronic hand eczema (CHE). |
approved |
|
|
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
gusacitinib |
Psoriasis |
COMPLETED |
Phase 2 |
NCT02969018 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
gusacitinib |
Atopic dermatitis |
COMPLETED |
Phase 2 |
NCT03531957 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
PF-6826647 |
Hidradenitis suppurativa |
COMPLETED |
Phase 2 |
NCT04092452 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
PF-6826647 |
Psoriasis |
COMPLETED |
Phase 2 |
NCT03895372 |
| JAK2 |
JAK |
Janus kinase (JAK) inhibitor |
izencitinib |
Crohn’s disease |
TERMINATED |
phase2/phase3 |
NCT03758443 |
| JAK2 |
JAK |
TYK2 inhibitor |
deucravacitinib |
Psoriasis |
ACTIVE,NOT RECRUITING |
Phase 3 |
NCT04036435 |
| JAK2 |
JAK |
TYK2 inhibitor |
deucravacitinib |
Psoriatic arthritis |
COMPLETED |
phas2 |
NCT03881059 |
| JAK2 |
JAK |
TYK2 inhibitor |
deucravacitinib |
Crohn’s disease |
ACTIVE,NOT RECRUITING |
Phase 2 |
NCT03599622 |
| JAK2 |
JAK |
TYK2 inhibitor |
deucravacitinib |
Systemic lupus erythematosus |
COMPLETED |
phase2 |
NCT03252587 |
| JAK2 |
JAK |
JAK1,JAK2,JAK3,intestinally restricted |
TD-1473 |
Ulcerative Colitis |
COMPLETED |
Phase 1 |
NCT02818686 |
| JAK2 |
JAK |
JAK1/JAK2/ACVR1 inhibitor |
Momelotinib (CYT387) |
intermediate- or high-risk myelofibrosis,including primary or secondary myelofibrosis,and disease-related anemia |
FDA approved |
|
|
| JAK2 |
JAK |
JAK2 |
Fedratinib |
intermediate-2 or high-risk primary or secondary (post-polycythemia
vera or post-essential thrombocythemia) myelofibrosis |
FDA approved |
|
|
| KRAS |
RAS |
KRASG12C |
Sotorasib (AMG 510) |
KRAS p.G12C Mutant Advanced Solid Tumors |
Active,not recruiting |
Phase 1Phase 2 |
Approved for previously treated advanced-stage KRASG12C-mutant NSCLC; further clinical trials ongoing (NCT03600883,NCT04185883,NCT04303780,NCT04933695,NCT04625647,NCT05398094,NCT05074810,NCT04380753,NCT05311709,NCT05054725,NCT05400577,NCT05180422,NCT04667234,NCT05198934,NCT05374538,NCT05313009,NCT05118854,NCT05273047,NCT05251038,NCT04892017,NCT04959981,NCT04720976) |
| KRAS |
RAS |
KRASG12C |
Sotorasib (AMG 510) |
adults with advanced non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C mutation who have received at least one prior systemic therapy |
FDA-Approved |
|
|
| KRAS |
RAS |
KRASG12C |
Adagrasib (MRTX849) |
Advanced Cancer |
Recruiting |
Phase 1Phase 2 |
Clinical trials (NCT03785249,NCT04330664,NCT04613596,NCT04793958,NCT04685135,NCT05162443,NCT05375994,NCT05263986,NCT04975256,NCT05178888,NCT04418661) |
| KRAS |
RAS |
KRASG12C |
D-1553 |
Solid Tumor,Adult |
Recruiting |
Phase 1Phase 2 |
Clinical trials (NCT04585035,NCT05383898,NCT05379946) |
| KRAS |
RAS |
KRASG12C |
JDQ443 |
KRAS G12C Mutant Solid Tumors |
Recruiting |
Phase 1Phase 2 |
Clinical trials (NCT04699188,NCT05132075,NCT05358249,NCT05329623) |
| KRAS |
RAS |
KRASG12C |
RG6330 (GDC-6036) |
Non-Small Cell Lung Cancer |
Recruiting |
Phase 1 |
Clinical trials (NCT04449874,NCT03178552) |
| KRAS |
RAS |
KRASG12C |
LY3537982 |
Carcinoma,Non-Small-Cell Lung |
Recruiting |
Phase 1 |
NCT04956640 |
| KRAS |
RAS |
KRASG12C |
BI 1823911 |
Solid Tumors,KRAS Mutation |
Active,not recruiting |
Phase 1 |
NCT04973163 |
| KRAS |
RAS |
KRASG12C |
JAB-21822 |
NSCLC |
Recruiting |
Phase 1Phase 2 |
Clinical trials (NCT05009329,NCT05194995,NCT05002270,NCT05276726,NCT05288205) |
| KRAS |
RAS |
KRASG12C |
JNJ-74699157 (ARS-3248) |
Neoplasms |
Completed |
Phase 1 |
NCT04006301 |
| KRAS |
RAS |
KRASG12C |
MK-1084 |
Advanced Solid Tumors |
Recruiting |
Phase 1 |
NCT05067283 |
| KRAS |
RAS |
KRASG12C |
RMC-6291 |
Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
Phase 1 |
NCT05462717 |
| KRAS |
RAS |
KRASG12D |
MRTX1133 |
Solid Tumor |
Recruiting |
Phase 1Phase 2 |
NCT05737706 |
| KRAS |
RAS |
KRASG12D |
MRTX1133 |
Advanced Solid Tumor |
Recruiting |
Phase 1Phase 2 |
NCT05737706 |
| KRAS |
RAS |
RASMULTI |
RMC-6236 |
Non-small Cell Lung Cancer (NSCLC) |
Recruiting |
Phase 1 |
Clinical trials (NCT05379985) |
| KRAS |
RAS |
KRASG12V |
Specific TCRs |
Pancreatic Cancer |
Recruiting |
Phase 1Phase 2 |
NCT04146298 |
| KRAS |
RAS |
KRASG12V |
Specific TCRs |
for uveal melanoma,a rare type of melanoma occurring in the eye |
FDA-Approved |
|
|
| KRAS |
RAS |
KRASG12C,KRASG12D,KRASG12V and KRASG13D |
mRNA-5671/V941 |
Neoplasms |
Completed |
Phase 1 |
NCT03948763 |
| KRAS |
RAS |
KRASG12C,KRASG12V,KRASG12D,KRASG12A,KRASG13D or KRASG12R |
Mutant KRAS-targeted long-peptide vaccine |
Colorectal Cancer |
Recruiting |
Phase 1 |
NCT04117087 |
| KRAS |
RAS |
KRASG12C,KRASG12V,KRASG12D or KRASG12R |
mDC3/8-KRAS vaccine |
Pancreatic Ductal Adenocarcinoma |
Active,not recruiting |
Phase 1 |
NCT03592888 |
| KRAS |
RAS |
KRASG12D or KRASG12R |
ELI-002 2P |
Minimal Residual Disease |
Active,not recruiting |
Phase 1 |
NCT04853017 |
| KRAS |
RAS |
KRASG12D mRNA |
iExosomes |
Metastatic Pancreatic Adenocarcinoma |
Active,not recruiting |
Phase 1 |
NCT03608631 |
| KRAS |
RAS |
KRAS Mut |
BI 1701963 (+ BI 3011441) |
Solid tumors |
recruiting |
phase 1 |
NCT04835714 |
| PITRM1 |
MP1 |
|
|
|
|
|
|
| PRKCQ |
PKC8 |
PKC8 inhibitor |
AEB071 |
Uveal Melanoma |
Completed |
Phase 1 |
NCT02273219 |
| PRKCQ |
PKC8 |
PKC8 inhibitor |
AEB071 |
de Novo Liver Transplantation |
Completed |
Phase 1 |
NCT00545259 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
LOXO-292 |
Non-Small Cell Lung Cancer |
Recruiting |
Phase 1Phase 2 |
NCT03157128 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
pralsetinib (BLU-667) |
RET-altered Non Small Cell Lung Cancer |
Active,not recruiting |
Phase 1Phase 2 |
NCT03037385 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
alectinib |
Non-Small Cell Lung Cancer |
Completed |
Phase 1Phase 2 |
NCT01871805 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
alectinib |
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) |
FDA-Approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Lenvatinib (E7080) |
Advanced Lung Cancer or Lung Cancer That Has Spread,Who Have Been Previously Treated,Unsuccessfully,With at Least 2 Different Treatments |
COMPLETED |
Phase 2 |
NCT01529112 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Lenvatinib (E7080) |
For the treatment of patients with locally recurrent or metastatic,progressive,radioactive iodine-refractory differentiated thyroid cancer
(DTC). (1.1)
• In combination with everolimus,for the treatment of patients with
advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy. (1.2)
• For the first-line treatment of patients with unresectable hepatocellular
carcinoma (HCC). (1.3)
• In combination with pembrolizumab,for the treatment of patients with
advanced endometrial carcinoma (EC) that is not MSI-H or dMMR who
have disease progression following prior systemic therapy in any setting
and are not candidates for curative surgery or radiation. (1.4 |
FDA approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Cabozantinib |
RET Positive NSCLC |
unknown status |
Phase 2 |
NCT04131543 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Cabozantinib |
patients with advanced renal cell carcinoma (RCC),patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib |
FDA approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Ponatinib |
Advanced Non-Small Cell Lung Cancer Harboring RET Translocations |
completed |
Phase 2 |
NCT01813734 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Ponatinib |
chronic phase,accelerated phase,or blast phase chronic myeloid leukemia (CML) |
FDA approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Sorafenib |
Unresectable hepatocellular carcinoma,Advanced renal cell carcinoma |
FDA approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
NEXAVAR (sorafenib) |
Advanced HCC |
RECRUITING |
phase4 |
NCT02733809 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Sunitinib |
RET Fusion Positive or FGFR2 Amplification,Refractory Solid Tumors |
completed |
not applicable |
NCT02450123 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Sunitinib |
Gastrointestinal stromal tumor (GIST) after disease progression on or
intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC). Progressive,well-differentiated pancreatic neuroendocrine tumors
(pNET) in patients with unresectable locally advanced or metastatic
disease |
FDA approved |
|
|
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Vandetanib |
Non-small Cell Lung Cancer Harboring RET Rearrangement |
completed |
Phase 2 |
NCT01823068 |
| RET |
KIF5B-RET |
KIF5B-RET inhibitor |
Vandetanib |
symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease |
FDA approved |
|
|
| RET |
RET |
Multikinase inhibitors (RET,vascular endothelial growth factor receptor (VEGFR),mesenchymal–epithelial transition (MET),ROS1,AXL,immunoglobulin-like and epidermal growth factor-like domains 2 (TIE2),and KIT) |
Cabozantinib |
RET Positive NSCLC |
unknown status |
Phase 2 |
NCT04131543 |
| RET |
RET |
Multikinase inhibitors (RET,vascular endothelial growth factor receptor (VEGFR),mesenchymal–epithelial transition (MET),ROS1,AXL,immunoglobulin-like and epidermal growth factor-like domains 2 (TIE2),and KIT) |
Cabozantinib |
patients with advanced renal cell carcinoma (RCC),patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,and epidermal growth factor receptor (EGFR) |
Vandetanib |
Non-small Cell Lung Cancer Harboring RET Rearrangement |
completed |
Phase 2 |
NCT01823068 |
| RET |
RET |
RET,VEGFR,and epidermal growth factor receptor (EGFR) |
Vandetanib |
symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,platelet-derived growth factor receptor (PDGFR),fibroblast growth factor (FGF),and c-KIT |
Lenvatinib(E7080) |
KIF5B-RET-Positive Adenocarcinoma of the Lung |
completed |
Phase 2 |
NCT01877083 |
| RET |
RET |
RET,VEGFR,platelet-derived growth factor receptor (PDGFR),fibroblast growth factor (FGF),and c-KIT |
Lenvatinib(E7080) |
Differentiated Thyroid Cancer (DTC),Renal Cell Carcinoma (RCC),Hepatocellular Carcinoma (HCC),Endometrial Carcinoma (EC) |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,PDGFR,FLT3,and KIT |
Sorafenib |
Unresectable hepatocellular carcinoma,Advanced renal cell carcinoma |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,PDGFR,c-KIT,and fms-related tyrosine kinase 3 [FLT3] |
Sunitinib |
RET Fusion Positive or FGFR2 Amplification,Refractory Solid Tumors |
completed |
not applicable |
NCT02450123 |
| RET |
RET |
RET,VEGFR,PDGFR,c-KIT,and fms-related tyrosine kinase 3 [FLT3] |
Sunitinib |
Gastrointestinal stromal tumor (GIST) after disease progression on or
intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC). Progressive,well-differentiated pancreatic neuroendocrine tumors
(pNET) in patients with unresectable locally advanced or metastatic
disease |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,PDGFR,and FGFR |
Nintedanib |
chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait)， adults with interstitial lung disease associated with systemic sclerosis or scleroderma,called SSc-ILD |
FDA approved |
|
|
| RET |
RET |
FGFR1,FGFR2,FGFR3,FGFR4,RET,KIT |
Ponatinib |
Advanced Non-Small Cell Lung Cancer Harboring RET Translocations |
completed |
Phase 2 |
NCT01813734 |
| RET |
RET |
FGFR1,FGFR2,FGFR3,FGFR4,RET,KIT |
Ponatinib |
chronic phase,accelerated phase,or blast phase chronic myeloid leukemia (CML) |
FDA approved |
|
|
| RET |
RET |
RET,VEGFR,FGFR,PDGFR,c-KIT,and TIE2 |
Regorafenib |
hepatocellular carcinoma (HCC or liver cancer) |
FDA approved |
|
|
| RET |
RET |
wild-type RET and oncogenic RET fusions (KIF5B-RET,CCDC6-RET,etc.) and mutations (V804L,V804M,and M918T) |
Pralsetinib(BLU-667) |
Thyroid Cancer,Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
Active,not recruiting |
phase 1/2 |
NCT03037385 |
| RET |
RET |
wild-type RET and oncogenic RET fusions (KIF5B-RET,CCDC6-RET,etc.) and mutations (V804L,V804M,and M918T) |
Pralsetinib(BLU-667) |
metastatic RET fusion-positive non-small cell lung cancer (NSCLC) |
FDA approved |
|
|
| RET |
RET |
wild-type RET and oncogenic RET fusions (KIF5B-RET,CCDC6-RET,etc.) and mutations (V804L,V804M,and M918T) |
Selpercatinib(LOXO-292) |
RET-mutant Medullary Thyroid Cancer,RET fusion-positive Non-Small Cell Lung Cancer |
Recruiting/active,not recruiting |
Phase 3 |
NCT04211337,NCT04194944,NCT04819100 |
| RET |
RET |
wild-type RET and oncogenic RET fusions (KIF5B-RET,CCDC6-RET,etc.) and mutations (V804L,V804M,and M918T) |
Selpercatinib(LOXO-292) |
locally advanced or metastatic RET fusion-positive solid tumors |
FDA approved |
|
|
| RHO |
Rho |
GGTase I inhibitor,target protein prenylation |
GGTI-2418 |
Advanced Malignancies |
UNKNOWN STATUS |
Phase 1 |
NCT03900442 |
| RHO |
Rho |
Dual inhibitor of PAK4 and NAMPT |
KPT-9274 |
Relapsed and Refractory Acute Myeloid Leukemia |
RECRUITING |
Phase 1 |
NCT04914845 |
| RHO |
Rho |
ATP-competitive,pyrrolopyrazole inhibitor of PAK4 |
PF-07304814 |
Viral Disease |
COMPLETED |
Phase 1 |
NCT04535167 |
| RHO |
Rho |
Multi-AGC kinase inhibitor with high specificity for ROCK1 and ROCK2 |
AT13148 |
Advanced Solid Tumours |
COMPLETED |
Phase 1 |
NCT01585701 |
| TP53 |
p53 |
p53 activator |
RG7112 |
Hematologic |
Completed |
Phase 1 |
NCT00623870 |
| TP53 |
p53 |
p53 activator |
RG7112 |
AML,Solid tumors |
Recruiting |
Phase 1Phase 2 |
NCT04029688 |
| TP53 |
p53 |
p53 activator |
RG7112 |
Solid tumors |
Recruiting |
Phase 2 |
NCT04589845 |
| TP53 |
p53 |
p53 activator |
RG7112 |
Glioblastoma |
Completed |
Phase 1Phase 2 |
NCT03158389 |
| TP53 |
p53 |
p53 activator |
SAR405838 |
Malignant neoplasm |
Completed |
Phase 1 |
NCT01636479 |
| TP53 |
p53 |
p53 activator |
SAR405838 |
Malignant neoplasm |
Completed |
Phase 1 |
NCT01985191 |
| TP53 |
p53 |
p53 activator |
Milademetan |
Advanced solid tumor,Lymphoma |
Completed |
Phase 1 |
NCT01877382 |
| TP53 |
p53 |
p53 activator |
Alrizomadlin |
Metastatic melanomas,Advanced solid tumors |
Recruiting |
Phase 1Phase 2 |
NCT03611868 |
| TP53 |
p53 |
p53 activator |
Alrizomadlin |
treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents |
FDA-Approved |
|
|
| TP53 |
p53 |
p53 activator |
KRT-232 |
MCC |
Recruiting |
Phase 1Phase 2 |
NCT03787602 |
| TP53 |
p53 |
p53 activator |
NVP-CGM097 |
Solid tumors |
Completed |
Phase 1 |
NCT01760525 |
| TP53 |
p53 |
p53 activator |
BI 907828 |
Solid tumors |
Recruiting |
Phase 1 |
NCT03449381 |
| TP53 |
p53 |
p53 activator |
Siremadlin |
Advanced solid tumors,Hematological neoplasm |
Completed |
Phase 1 |
NCT02143635 |
| TP53 |
p53 |
p53 activator |
Siremadlin |
Solid tumors |
Completed |
Phase 1 |
NCT02343172 |
| TP53 |
p53 |
p53 activator |
APR-246 |
Refractory hematologic tumor,Prostate cancer |
Completed |
Phase 1 |
NCT00900614 |
| TP53 |
p53 |
p53 activator |
APR-246 |
Myeloid Neoplasms with p53 mutations |
Completed |
Phase 1Phase 2 |
NCT03072043 |
| TP53 |
p53 |
p53 activator |
APR-246 |
MDS with p53 mutations |
Completed |
Phase 3 |
NCT03745716 |
| TP53 |
p53 |
p53 activator |
COTI-2 |
Advanced solid tumors with p53 mutations |
Unknown status |
Phase 1 |
NCT02433626 |
| TP53 |
p53 |
p53 activator |
Tanespimycin |
Multiple myeloma with p53 mutations |
Completed |
Phase 2Phase 3 |
NCT00514371 |
| TP53 |
p53 |
p53 activator |
Atorvastatin Calcium |
Colorectal Carcinoma,Ulcerative Colitis with p53 mutations |
Recruiting |
Phase 2 |
NCT04767984 |
| TP53 |
p53 |
p53 activator |
Atorvastatin Calcium |
To reduce the risk of. Myocardial infarction (MI),stroke,revascularization procedures,and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD |
FDA-Approved |
|
|
| TP53 |
p53 |
p53 activator |
Atorvastatin |
Advanced solid tumors with p53 mutations |
Recruiting |
Phase 1 |
NCT03560882 |
| TP53 |
p53 |
p53 activator |
Atorvastatin |
To reduce the risk of. Myocardial infarction (MI),stroke,revascularization procedures,and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD |
FDA-Approved |
|
|
| TP53 |
p53 |
p53 activator |
MK-1775 |
Platinum-sensitive Ovarian Tumors with p53 Mutations |
Completed |
Phase 2 |
NCT01357161 |
| TP53 |
p53 |
p53 activator |
MK-1775 |
Epithelial ovarian cancer with p53 Mutation |
Completed |
Phase 2 |
NCT01164995 |
| TP53 |
p53 |
p53 activator |
MK-1775 |
Ovarian,Fallopian Tube,Peritoneal cancer with p53 mutations |
Completed |
Phase 2 |
NCT02272790 |
| TP53 |
p53 |
p53 activator |
SGT-53 plus gemcitabine/nab-paclitaxel |
Pancreatic cancer |
Recruiting |
Phase II |
NCT02340117 |
| TP53 |
p53 |
p53 activator |
Ad-p53 plus immunotherapy |
Solid tumours,lymphoma |
Unknown status |
Phase II |
NCT03544723 |
| TP53 |
p53 |
p53 activator |
MVAp53 plus pembrolizumab |
Multiple cancers |
Active,not recruiting |
Phase 1 |
NCT02432963 |
| TP53 |
p53 |
p53 activator |
MVAp53 plus pembrolizumab |
Multiple cancers |
Active,not recruiting |
Phase II |
NCT03113487 |
| TP53 |
p53 |
p53 activator |
Tedopi plus nivolumab and docetaxel |
NSCLC |
Recruiting |
Phase II |
NCT04884282 |
| TP53 |
p53 |
p53 activator |
p53 RNA vaccine |
TNBC |
Completed |
Phase I |
NCT02316457 |
| TP53 |
p53 |
p53 activator |
Idasanutlin plus ixazomib |
Multiple myeloma |
Active,not recruiting |
Phase I/II |
NCT02633059 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus chemotherapy |
Multiple myeloma |
Recruiting |
Phase I |
NCT03031730 |
| TP53 |
p53 |
p53 activator |
KRT-232 MT |
Glioblastoma,gliosarcoma |
Recruiting |
Phase I |
NCT03107780 |
| TP53 |
p53 |
p53 activator |
Idasanutlin plus radiotherapy |
Glioblastoma |
Completed |
Phase I/II |
NCT03158389 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus radiotherapy |
Soft tissue sarcoma |
Active,not recruiting |
Phase I |
NCT03217266 |
| TP53 |
p53 |
p53 activator |
APG-115 plus pembrolizumab |
Multiple cancers |
Recruiting |
Phase I/II |
NCT03611868 |
| TP53 |
p53 |
p53 activator |
KRT-232 MT |
Myelofibrosis |
Recruiting |
Phase II/III |
NCT03662126 |
| TP53 |
p53 |
p53 activator |
KRT-232 MT |
Polycythaemia vera |
Unknown status |
Phase II |
NCT03669965 |
| TP53 |
p53 |
p53 activator |
APG-115 MT |
Salivary gland cancer |
Recruiting |
Phase I/II |
NCT03781986 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus avelumab |
Merkel cell carcinoma |
Recruiting |
Phase I/II |
NCT03787602 |
| TP53 |
p53 |
p53 activator |
ASTX295 |
Solid tumours |
Active,not recruiting |
Phase I/II |
NCT03975387 |
| TP53 |
p53 |
p53 activator |
Idasanutlin plus chemotherapy or venetoclax |
AML,ALL,neuroblastoma,solid tumours |
Recruiting |
Phase I/II |
NCT04029688 |
| TP53 |
p53 |
p53 activator |
Siremadlin plus ruxolitinib |
Myelofibrosis |
Active,not recruiting |
Phase I/II |
NCT04097821 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus cytarabine or decitabine |
AML |
Active,not recruiting |
Phase I/II |
NCT04113616 |
| TP53 |
p53 |
p53 activator |
HDM201 plus ribociclib |
Solid tumours |
Recruiting |
Phase II |
NCT04116541 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus cytarabine plus idarubicin |
AML |
Active,not recruiting |
Phase I |
NCT04190550 |
| TP53 |
p53 |
p53 activator |
APG-115 MT/APG-115 plus azacitidine or cytarabine |
AML,MDS |
Recruiting |
Phase I |
NCT04275518 |
| TP53 |
p53 |
p53 activator |
APG-115 MT or APG-115 plus 5-azacitidine |
AML,CMML,MDS |
Recruiting |
Phase I/II |
NCT04358393 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus ruxolitinib |
Myelofibrosis |
Recruiting |
Phase I/II |
NCT04485260 |
| TP53 |
p53 |
p53 activator |
APG-115 MT or APG-115 plus APG-2575 |
T-prolymphocytic leukaemia |
Recruiting |
Phase II |
NCT04496349 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus acalabrutinib |
DLBCL,CLL,NHL |
Recruiting |
Phase I/II |
NCT04502394 |
| TP53 |
p53 |
p53 activator |
Idasanutlin MT |
Solid tumours |
Recruiting |
Phase II |
NCT04589845 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus TL-895 |
Myelofibrosis |
Recruiting |
Phase I/II |
NCT04640532 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus TL-895 |
AML |
Active,not recruiting |
Phase I/II |
NCT04669067 |
| TP53 |
p53 |
p53 activator |
APG-115 plus toripalimab |
Liposarcoma,solid tumours |
Recruiting |
Phase I/II |
NCT04785196 |
| TP53 |
p53 |
p53 activator |
KRT-232 plus dasatinib or nilotinib |
CML |
Recruiting |
Phase I/II |
NCT04835584 |
| TP53 |
p53 |
p53 activator |
KRT-232 MT |
Myelofibrosis |
Recruiting |
Phase II |
NCT04878003 |
| TP53 |
p53 |
p53 activator |
ALRN-6924 MT or ALRN-6924 plus cytarabine |
Leukaemia,brain tumours,solid tumours,lymphoma |
Completed |
Phase I |
NCT03654716 |
| TP53 |
p53 |
p53 activator |
ALRN-6924 plus paclitaxel |
Multiple tumours |
Active,not recruiting |
Phase I |
NCT03725436 |
| TP53 |
p53 |
p53 activator |
Arsenic trioxide plus decitabine |
MDS,AML |
Recruiting |
Phase I |
NCT03855371 |
| TP53 |
p53 |
p53 activator |
Arsenic trioxide MT |
Ovarian cancer,endometrial cancer |
Unknown status |
Not Applicable |
NCT04489706 |
| TP53 |
p53 |
p53 activator |
PC14586 |
Solid tumours |
Recruiting |
Phase I/II |
NCT04585750 |
| TP53 |
p53 |
p53 activator |
Arsenic trioxide MT |
Multiple tumours |
Unknown status |
Phase II |
NCT04695223 |
| TP53 |
p53 |
p53 activator |
Arsenic trioxide MT |
Solid tumours |
Recruiting |
Phase II |
NCT04869475 |
| TP53 |
p53 |
p53 activator |
APR-246 plus azacitidine |
MDS |
Completed |
Phase III |
NCT03745716 |
| TP53 |
p53 |
p53 activator |
APR-246 plus pembrolizumab |
Multiple cancers |
Completed |
Phase I/II |
NCT04383938 |
| TP53 |
p53 |
p53 activator |
Sodium stibogluconate MT |
MDS,AML |
Recruiting |
Phase II |
NCT04906031 |
| IL13 |
|
IL13 inhibitor |
CM310 |
Chronic Rhinosinusitis With Nasal Polyps |
Unknown status |
Phase 2 |
NCT05131464 |
| IL13 |
|
IL13 inhibitor |
CM310 |
Moderate-to-severe Atopic Dermatitis |
Completed |
Phase 2 |
NCT04805411 |
| IL13 |
|
IL13 inhibitor |
CBP-201 |
Atopic Dermatitis |
Active,not recruiting |
Phase 2 |
NCT05905133 |
| IL13 |
|
IL13 inhibitor |
CBP-201 |
Moderate-to-severe Atopic Dermatitis |
Completed |
Phase 2 |
NCT05017480 |
| IL13 |
|
IL13 inhibitor |
Lebrikizumab |
Asthma |
Completed |
Phase 2 |
NCT01545453 |
| IL13 |
|
IL13 inhibitor |
Lebrikizumab |
Atopic Dermatitis |
Not yet recruiting |
Phase 3 |
NCT05990725 |
| IL13 |
|
IL13 inhibitor |
tralokinumab |
moderate to severe atopic dermatitis |
FDA-Approved |
|
|
| IL13 |
|
IL13 inhibitor |
tralokinumab |
Atopic Dermatitis |
Completed |
Phase 3 |
NCT05194540 |
| IL13 |
|
IL13 inhibitor |
tralokinumab |
Ulcerative Colitis |
Completed |
Phase 2 |
NCT01482884 |
| IL4R |
|
IL4R inhibitor |
Dupilumab |
pediatric patients aged 1 to 11 years,weighing at least 15 kg,with eosinophilic esophagitis (EoE) |
FDA-Approved |
|
|
| IL4R |
|
IL4R inhibitor |
Dupilumab |
Atopic Dermatitis |
Not yet recruiting |
Phase 4 |
NCT05285839 |
| IL4R |
|
IL4R inhibitor |
Dupilumab |
Dermal Hypersensitivity Reaction |
Recruiting |
Phase 4 |
NCT06012448 |
| IL4R |
|
IL4R inhibitor |
Lebrikizumab |
Asthma |
Completed |
Phase 2 |
NCT01545453 |
| IL4R |
|
IL4R inhibitor |
Lebrikizumab |
Atopic Dermatitis |
Not yet recruiting |
Phase 3 |
NCT05990725 |
| IL4R |
|
IL4R inhibitor |
tralokinumab |
moderate to severe atopic dermatitis |
FDA-Approved |
|
|
| IL4R |
|
IL4R inhibitor |
tralokinumab |
Atopic Dermatitis |
Completed |
Phase 3 |
NCT05194540 |
| IL4R |
|
IL4R inhibitor |
tralokinumab |
Ulcerative Colitis |
Completed |
Phase 2 |
NCT01482884 |
| IL4R |
|
IL4R inhibitor |
Pascolizumab |
Tuberculosis,Pulmonary |
Unknown status |
Phase 2 |
NCT01638520 |
| IL4R |
|
IL4R inhibitor |
Pascolizumab |
Asthma |
Completed |
Phase 2 |
NCT00024544 |
| IL4R |
|
IL4R inhibitor |
Pitrakinra |
Atopic Eczema |
Completed |
Phase 2 |
NCT00676884 |
| IL4R |
|
IL4R inhibitor |
Pitrakinra |
Asthma |
Completed |
Phase 1 |
NCT00785668 |
| IL4R |
|
IL4R inhibitor |
AMG 317 |
Asthma |
Completed |
Phase 2 |
NCT00436670 |
| NTRK1 |
|
NTRK1/2/3 |
LOXO-101 |
Solid Tumors Harboring NTRK Fusion |
Active,not recruiting |
Phase 2 |
NCT02576431 |
| NTRK1 |
|
NTRK1/2/3 |
LOXO-101 |
Differentiated Thyroid Cancer |
Recruiting |
Phase 2 |
NCT05783323 |
| NTRK1 |
|
NTRK1/2/3,ALK,ROS1 |
Entrectinib |
Solid tumor |
Active,not recruiting |
Phase 2 |
NCT02568267b |
| NTRK1 |
|
NTRK1/2/3,ALK,ROS1 |
Entrectinib |
Carcinoma,Non-Small-Cell Lung |
Recruiting |
Phase 3 |
NCT04603807 |
| NTRK1 |
|
NTRK1/2/3,ALK,ROS1 |
Entrectinib |
Solid Tumors |
Recruiting |
Phase 2 |
NCT04589845 |
| NTRK1 |
|
NTRK1/2/3 |
LOXO-195 |
Solid Tumors Harboring NTRK Fusion |
Completed |
Phase 1 |
NCT04275960 |
| NTRK1 |
|
NTRK1/2/3,ALK |
TSR-011 |
Solid Tumors |
Completed |
Phase 1Phase 2 |
NCT02048488 |
| NTRK1 |
|
NTRK1/2/3,ALK |
TSR-011 |
Lymphomas |
Completed |
Phase 1Phase 2 |
NCT02048488 |
| NTRK1 |
|
NTRK1/2/3,KDR,MET,KIT,PDGFR,DDR2 |
MGCD-516 |
Solid tumor |
Completed |
Phase 1 |
NCT02219711 |
| NTRK1 |
|
NTRK1/2/3,KDR,MET,KIT,PDGFR,DDR2 |
MGCD-516 |
Liposarcoma |
Active,not recruiting |
Phase 2 |
NCT02978859 |
| NTRK1 |
|
NTRK1/2/3,KDR,MET,KIT,PDGFR,DDR2 |
MGCD-516 |
NSCLC |
Completed |
Phase 2 |
NCT02954991 |
| NTRK1 |
|
NTRK1/2/3,ROS1 |
DS-6051b |
Advanced Solid Malignant Tumors |
Completed |
Phase 1 |
NCT02675491 |
| NTRK1 |
|
NTRK1/2/3,ROS1 |
DS-6051b |
advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) |
FDA approved |
|
|
| NTRK1 |
|
NTRK1/2/3,ROS1 |
DS-6051b |
Breast Cancer |
Not yet recruiting |
Phase 2 |
NCT06214793 |
| NTRK1 |
|
NTRK2,RET,KIT,FLT3,MET,KDR,FLT1,FLT4,AXL |
Cabozantinib |
Meningioma |
Recruiting |
Phase 2 |
NCT05425004 |
| NTRK1 |
|
NTRK2,RET,KIT,FLT3,MET,KDR,FLT1,FLT4,AXL |
Cabozantinib |
RET Positive NSCLC |
unknown status |
Phase 2 |
NCT04131543 |
| NTRK1 |
|
NTRK2,RET,KIT,FLT3,MET,KDR,FLT1,FLT4,AXL |
Cabozantinib |
patients with advanced renal cell carcinoma (RCC),patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib |
FDA approved |
|
|
| NTRK1 |
|
NTRK1/2/3,MET,AXL,ROS1,MKNK1,MKNK2,FLT3,TEK,DDR1,DDR2 |
Merestinib |
Carcinoma,Non-Small-Cell Lung |
Active,not recruiting |
Phase 2 |
NCT02920996 |
| NTRK1 |
|
NTRK1/2/3,MET,AXL,ROS1,MKNK1,MKNK2,FLT3,TEK,DDR1,DDR2 |
Merestinib |
Solid Tumor |
Active,not recruiting |
Phase 2 |
NCT02920996 |
| NTRK1 |
|
NTRK inhibitor |
Repotrectinib |
advanced lung cancers that have a genetic change called a ROS1 gene fusion |
FDA-Approved |
|
|
| NTRK1 |
|
NTRK inhibitor |
Repotrectinib |
Carcinoma,Non-Small-Cell Lung |
Recruiting |
Phase 3 |
NCT06140836 |
| NTRK1 |
|
NTRK inhibitor |
Repotrectinib |
Locally Advanced Solid Tumors |
Recruiting |
Phase 1Phase 2 |
NCT03093116 |
| NTRK1 |
|
NTRK inhibitor |
PBI-200 |
Absorption,Metabolism and Excretion in Healthy Volunteers |
Completed |
Phase 1 |
NCT05238337 |
| NTRK1 |
|
NTRK inhibitor |
PBI-200 |
Formulation Bridging |
Completed |
Phase 1 |
NCT05690932 |
| NTRK1 |
|
NTRK inhibitor |
PBI-200 |
NTRK fusion–positive solid tumors |
FDA-Approved |
|
|
| NTRK1 |
|
NTRK inhibitor |
AB-106 |
Metastatic Breast Cancer |
Not yet recruiting |
Phase 2 |
NCT06214793 |
| NTRK1 |
|
NTRK inhibitor |
AB-106 |
Non Small Cell Lung Cancer |
Recruiting |
Phase 2 |
NCT04919811 |
| NTRK1 |
|
NTRK inhibitor |
XZP-5955 |
Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Recruiting |
Phase 1Phase 2 |
NCT04996121 |
| NTRK1 |
|
NTRK inhibitor |
FCN-011 |
Advanced Solid Tumor |
Unknown status |
Phase 1 |
NCT04687423 |
| NTRK1 |
|
NTRK inhibitor |
Selitrectinib |
Solid Tumors Harboring NTRK Fusion |
Completed |
Phase 1 |
NCT03215511 |
| NTRK1 |
|
NTRK inhibitor |
SIM1803-1A |
Advanced or Metastatic Solid Tumors With NTRK,ROS1 or ALK Gene Fusion |
Unknown status |
Phase 1 |
NCT04671849 |
| JAK2 |
JAK |
JAK |
SAR302503 （TQ101348 ） |
Myelofibrosis |
COMPLETED |
Phase 3 |
NCT01437787 |
| JAK2 |
JAK2 |
JAK1/2, IRAK1 |
Pacritinib |
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
RECRUITING |
Phase 3 |
NCT03165734 |
| JAK2 |
JAK2 |
JAK1/2, IRAK1 |
Pacritinib |
Relapsed/Refractory T-cell Lymphoproliferative Neoplasms |
RECRUITING |
Phase 2 |
NCT04858256 |
| JAK2 |
JAK2 |
FLT3, JAK2/STAT5 |
Lestaurtinib (CEP7O1) |
Newly Diagnosed Acute Lymphoblastic Leukemia |
COMPLETED |
Phase 3 |
NCT00557193 |
| JAK2 |
JAK2 |
FLT3, JAK2/STAT5 |
Lestaurtinib (CEP7O1) |
Polycythemia Vera or Essential Thrombocytosis |
COMPLETED |
Phase 2 |
NCT00586651 |
| JAK2 |
JAK2 |
JAK2 |
LY2784544 ( Gandotinib) |
Myeloproliferative Neoplasms |
ACTIVE, NOT RECRUITING |
Phase 2 |
NCT01594723 |
| JAK2 |
JAK2 |
JAK2 |
NS-018 |
Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF |
COMPLETED |
Phase 2 |
NCT01423851 |
| JAK2 |
JAK2 |
JAK2 |
AZD1480 |
Myeloproliferative Diseases |
COMPLETED |
Phase 1 |
NCT00910728 |
| JAK2 |
JAK |
JAK1/2 |
Deuruxolitinib Phosphate |
斑秃 |
FDA approve |
|
|
| JAK2 |
JAK |
JAK1/2/3, TYK2 |
Upadacitinib hemihydrate |
多关节型幼年特发性关节炎, 克罗恩病，强直性脊柱炎，银屑病关节炎，溃疡性结肠炎，特应性皮炎，非放射性轴性脊柱关节炎，类风湿关节炎 |
FDA approve |
|
|
| JAK2 |
JAK |
JAK1/2/3 |
Tofacitinib Citrate |
强直性脊柱炎，银屑病关节炎，溃疡性结肠炎,类风湿关节炎,幼年型关节炎 |
FDA approve |
|
|
| JAK2 |
JAK |
JAK1/2 |
Pumecitinib |
特应性皮炎 |
进行中 |
临床3期 |
CTR20230499 |
| JAK2 |
JAK |
Aurora A x Aurora B x CSF-1R x FGFR1 x FGFR2 x FGFR3 x JAK1 x JAK2 x VEGFR |
TT-00420 (Tinengotinib) |
FGFR-altered in Cholangiocarcinoma |
Recruiting |
Phase 3 |
NCT05948475 |
| AURKA |
AuroraA |
Aurora A x Aurora B x CSF-1R x FGFR1 x FGFR2 x FGFR3 x JAK1 x JAK2 x VEGFR |
TT-00420 (Tinengotinib) |
FGFR-altered in Cholangiocarcinoma |
Recruiting |
Phase 3 |
NCT05948475 |
| JAK2 |
JAK |
Aurora A x Aurora B x CSF-1R x FGFR1 x FGFR2 x FGFR3 x JAK1 x JAK2 x VEGFR |
TT-00420 (Tinengotinib) |
Advanced Solid Tumors |
Completed |
Phase 2 |
NCT04742959 |
| AURKA |
AuroraA |
Aurora A x Aurora B x CSF-1R x FGFR1 x FGFR2 x FGFR3 x JAK1 x JAK2 x VEGFR |
TT-00420 (Tinengotinib) |
Advanced Solid Tumors |
Completed |
Phase 2 |
NCT04742959 |
| JAK2 |
JAK2 |
CDK6 x FLT3 x JAK2 |
Flunotinib maleate |
原发性血小板增多症后骨髓纤维化 |
进行中 |
临床2期 |
CTR20241632 |
| JAK2 |
JAK2 |
CDK6 x FLT3 x JAK2 |
Flunotinib maleate |
骨髓肿瘤 |
进行中 |
临床1期 |
CTR20211856 |
| JAK2 |
JAK |
ALK2 x JAK1 x JAK2 x JAK3 x TYK2 |
Jaktinib Hydrochloride |
原发性血小板增多症后骨髓纤维化，真性红细胞增多症后骨髓纤维化，原发性骨髓纤维化 |
NMPA申请上市 |
|
|
| JAK2 |
JAK |
JAK1 x JAK2 x ROCK1 x ROCK2 |
Rovadicitinib |
骨髓纤维化 |
NMPA申请上市 |
|
|
| TP53 |
P53 |
p53刺激剂 |
Recombinant human adenovirus type 5 (Sunway Biotech) |
鼻咽癌 |
NMPA approve |
|
|
| TP53 |
P53 |
p53刺激剂 |
Recombinant Human Ad-p53 |
鼻咽肿瘤 |
NMPA approve |
|
|
| TP53 |
P53 |
p53刺激剂 |
Nadolol |
心绞痛,心动过缓，高血压，甲亢，偏头痛，慢性咳嗽，慢性阻塞性肺疾病，轻度持续性哮喘，哮喘 |
FDA approve |
|
|
| TP53 |
P53 |
NF-κB x p53 x sPLA2 |
Mepacrine hydrochloride |
Creutzfeldt-Jakob Disease |
Completed |
Phase 2 |
NCT00183092 |
| TP53 |
P53 |
NF-κB x p53 x sPLA2 |
Mepacrine hydrochloride |
Stage IIIB-IV Non-Small Cell Lung Cancer |
Completed |
Phase 2 |
NCT01839955 |
| ABCG2 |
ABCG2 |
ABCG2 x P-gp |
BST-204 |
恶病质 |
\ |
Phase 2 |
WHO临床(EUCTR2017-003271-61-DE) |
| ABCG2 |
ABCG2 |
XO inhibitor |
Febuxostat |
hyperuricemia |
FDA approve |
|
|